{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"11.8","value":"7.1"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.","groupId":"OG001","lowerLimit":"2.8","upperLimit":"NA","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"OS was defined as the time from the start of study treatment until the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with microsatellite stable, locally advanced or metastatic CRC that was previously treated with at least 3 prior lines of therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG000","title":"Dose Expansion Phase: Cohort A: CRC"},{"description":"Patients with locally advanced or metastatic ATC and who had a BRAFV600E mutation were previously treated with 1 line of systemic therapy (not including radiation therapy) with a BRAF-targeted therapy received surufatinib 300 mg orally QD in combination with tislelizumab 200 mg IV infusion Q3W until PD, unacceptable toxicity, withdrawal of consent, new anticancer therapy, lost to follow-up, or death.","id":"OG001","title":"Dose Expansion Phase: Cohort F: ATC"}],"paramType":"MEDIAN","populationDescription":"The SAS included all enrolled patients who received at least 1 dose of surufatinib or tislelizumab. As pre-specified in the protocol and statistical analysis plan (SAP), OS was assessed only in Cohort A (CRC) and Cohort F (ATC) of the dose expansion phase.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment (Day 1) up to date of death due to any cause, up to approximately 42 months","title":"Dose Expansion Phase (Cohorts A and F): Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}